List view / Grid view
The trial of DSP-0038, an Alzheimer’s disease psychosis drug designed using artificial intelligence, will assess its ability to improve the behavioural and psychological symptoms of dementia.
The A2a receptor antagonist, which aims to inhibit the immunosuppression of T cells by adenosine, was in part designed using Exscientia’s 3D evolutionary artificial intelligence platform.
The developers of DSP-1181, a drug created using AI, announced that it has entered a Phase I clinical trial for the treatment of obsessive-compulsive disorder (OCD).
